REPL
REPL
NASDAQ · Biotechnology

Replimune Group Inc

Small-Cap Stocks Biotech Stocks Healthcare Stocks
$10.19
+0.19 (+1.90%)
As of Jun 21, 10:18 PM ET ·
REPL News1 articles
Replimune Surges 85% on FDA Priority Review for Melanoma Drug
Replimune shares soared 85% after the FDA agreed to a priority review for its melanoma drug RP1, following a previous rejection. New trial data is expected soon.
Markets